D. Walker

发表

Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up*

J. Karagianis, K. Ledrew, D. Walker, 2003, Current medical research and opinion.

Profile of Adverse Events with Duloxetine Treatment

A. Crucitti, S. Brunton, M. Robinson, 2010, Drug safety.

Weight change and atypical antipsychotic treatment in patients with schizophrenia.

B. Jones, B. Kinon, B. Basson, 2001, The Journal of clinical psychiatry.

The efficacy of tadalafil in clinical populations.

W. Shen, I. Eardley, M. O'Leary, 2005, The journal of sexual medicine.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder

K. Day, D. Walker, D. Clemow, 2015, Postgraduate medicine.

Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial.

M. Thase, M. Detke, G. Maina, 2009, The Journal of clinical psychiatry.

Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.

Chien-Te Lee, M. Mazlan, M. Wong, 2002, The Journal of clinical psychiatry.

Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.

M. Detke, Charles R. Yang, A. Montejo, 2011, The journal of sexual medicine.

Tadalafil for Treatment of Erectile Dysfunction in Men on Antidepressants

R. Segraves, R. Dickson, D. Walker, 2007, Journal of clinical psychopharmacology.

Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.

M. Backonja, Shuyu Zhang, V. Skljarevski, 2010, Pain medicine.

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

M. Detke, L. Arnold, I. Russell, 2008, PAIN.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

M. Detke, C. Mallinckrodt, Fujun Wang, 2006, European Psychiatry.

Safety and Tolerability of Duloxetine at 60 mg Once Daily in Elderly Patients With Major Depressive Disorder

C. Katona, J. Raskin, D. Desaiah, 2008, Journal of clinical psychopharmacology.

Estimation of minimum clinically important difference for pain in fibromyalgia

L. Arnold, I. Russell, D. Kajdasz, 2011, Arthritis care & research.

A Double-Blind, Randomized Comparison of the Efficacy and Safety of Intramuscular Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients Diagnosed With Bipolar Mania

M. Tohen, P. Janicak, A. Breier, 2001, Journal of clinical psychopharmacology.

Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol

T. Inada, C. Beasley, D. Walker, 2003, International clinical psychopharmacology.

Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine.

R. Bennett, I. Russell, D. Kajdasz, 2012, Clinical therapeutics.

Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

L. Citrome, R. Holt, V. P. Hoffmann, 2011, Clinical drug investigation.

The Potential for Misuse and Abuse of Medications in ADHD: A Review

D. Walker, D. Clemow, 2014, Postgraduate medicine.

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.

M. Detke, I. Russell, D. Kajdasz, 2010, Seminars in arthritis and rheumatism.

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials

D. Kajdasz, P. Mease, P. Crits-Christoph, 2009, Clinical Rheumatology.

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.

Dieter Naber, J. Kane, D. Naber, 2005, The American journal of psychiatry.

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

James Russell, J. Erickson, E. Dunayevich, 2007, International clinical psychopharmacology.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

M. Thase, M. Bauer, J. Russell, 2008, Journal of psychiatric research.

Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence.

T. Wilens, P. Trzepacz, L. Adler, 2009, The American journal on addictions.

Adverse Events in Healthy Subjects Exposed to Single and Multiple Doses of LY2140023 Monohydrate: Pooled Results From 10 Phase 1 Studies

E. T. Wondmagegnehu, B. Kinon, S. Lowe, 2012, Journal of clinical psychopharmacology.

Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

M. DelBello, D. D'souza, H. Detke, 2017, Child and Adolescent Psychiatry and Mental Health.

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

G. Tollefson, C. Beasley, V. Sutton, 2003, Journal of clinical psychopharmacology.

Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.

M. Fava, S. Brecht, C. Wiltse, 2009, Journal of affective disorders.

Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms.

O. Brawman‐Mintzer, J. Raskin, C. Wiltse, 2007, Psychiatry (Edgmont (Pa. : Township)).

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder

J. Erickson, M. Detke, D. Nutt, 2008, Journal of psychopharmacology.

A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.

R. Peveler, D. Quail, D. Walker, 2008, Journal of affective disorders.

Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials

A. Schacht, L. Berggren, D. Walker, 2014 .

Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.

P. Kothare, M. Mitchell, K. Jen, 2013, Clinical therapeutics.

Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

I. Bitter, V. Mačiulis, M. Dossenbach, 2004, Current therapeutic research, clinical and experimental.

Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics

D. Kajdasz, J. Raskin, D. Walker, 2006, International clinical psychopharmacology.

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder

D. Kajdasz, A. Tylee, J. Raskin, 2006, International journal of clinical practice.

Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

L. Citrome, R. Holt, V. P. Hoffmann, 2011, Clinical drug investigation.

Evaluation of duloxetine for chronic pain conditions.

P. Mease, D. Walker, K. Alaka, 2011, Pain management.

Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder

P. Llorca, J. Russell, C. Allgulander, 2011, Human psychopharmacology.

Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence.

T. Wilens, P. Trzepacz, L. Adler, 2009, The American journal on addictions.